International: +1-347-960-6455
Fecal Incontinence Therapeutics - Pipeline Analysis 2018

Fecal Incontinence Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10026 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Gastroenterology
Select License Type

Fecal incontinence, also known as accidental bowel leakage, refers to the inability of a person to control bowel movement including stools and mucus. Urge incontinence is a common form of fecal incontinence that occur due to pelvic muscle injury or nerve damage. Passive incontinence is another type of fecal incontinence in which passing of stools is unknown to the patient. Some of the risk factor associated with fecal incontinence are gastrointestinal disorders, such as diarrhoea, constipation, and hemorrhoids. RDD Pharma Ltd. is in the process of developing RDD-0315 as an alpha-adrenergic receptor agonist for the treatment of fecal incontinence. The company has recently completed a successful Phase 2a study of RDD 0315 in fecal incontinence, which reached the primary endpoint (lowered frequency of incontinence events).

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.